Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease

Citation for published version:
Kennedy, NA, Kalla, R, Warner, B, Gambles, CJ, Musy, R, Reynolds, S, Dattani, R, Nayee, H, Felwick, R, Harris, R, Marriott, S, Senanayake, SM, Lamb, CA, Al-Hilou, H, Gaya, DR, Irving, PM, Mansfield, J, Parkes, M, Ahmad, T, Cummings, JRF, Arnott, ID, Satsangi, J, Lobo, AJ, Smith, M, Lindsay, JO & Lees, CW 2014, 'Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients' Alimentary Pharmacology and Therapeutics. DOI: 10.1111/apt.12980

Digital Object Identifier (DOI):
10.1111/apt.12980

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Alimentary Pharmacology and Therapeutics

Publisher Rights Statement:
© 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients

N. A. Kennedy*, R. Kalla*, B. Warner†, C. J. Gambles*, R. Musy*, S. Reynolds‡, R. Dattani§, H. Nayee§, R. Felwick¶, R. Harris†, S. Marriott**, J. R. F. Cummings§, I. D. Arnott*, J. Satsangi*, A. J. Lobo‡, M. Smith, J. O. Lindsay§ & C. W. Lees*

*Gastrointestinal Unit, Western General Hospital, Edinburgh, UK.
†Gastroenterology, Royal Sussex County Hospital, Brighton, UK.
‡Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Sheffield, UK.
§Gastroenterology, Barts Health NHS Trust, London, UK.
*Gastroenterology, Southampton General Hospital, Southampton, UK.
**University of Exeter Medical School and Royal Devon and Exeter NHS Foundation Trust.
††Gastroenterology Research Unit, Addenbrooke's Hospital, Cambridge, UK.
‡‡Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
§§Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
**Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
***Gastroenterology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Correspondence to:
Dr C. W. Lees, Gastrointestinal Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.
E-mail: Charlie.lees@ed.ac.uk

Publication data
Submitted 30 June 2014
First decision 18 July 2014
Resubmitted 30 August 2014
Accepted 14 September 2014

This article was accepted for publication after full peer-review.

SUMMARY

Background
Thiopurines (azathioprine and mercaptopurine) remain integral to most medical strategies for maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). Indefinite use of these drugs is tempered by long-term risks. While clinical relapse is noted frequently following drug withdrawal, there are few published data on predictive factors.

Aim
To investigate the success of planned thiopurine withdrawal in patients in sustained clinical remission to identify rates and predictors of relapse.

Methods
This was a multicentre retrospective cohort study from 11 centres across the UK. Patients included had a definitive diagnosis of IBD, continuous thiopurine use ≥3 years and withdrawal when in sustained clinical remission. All patients had a minimum of 12 months follow-up post drug withdrawal. Primary and secondary end points were relapse at 12 and 24 months respectively.

Results
237 patients were included in the study (129 CD; 108 UC). Median duration of thiopurine use prior to withdrawal was 6.0 years (interquartile range 4.4–8.4). At follow-up, moderate/severe relapse was observed in 23% CD and 12% UC patients at 12 months, 39% CD and 26% UC at 24 months. Relapse rate at 12 months was significantly higher in CD than UC (P = 0.035). Elevated CRP at withdrawal was associated with higher relapse rates at 12 months for CD (P = 0.005), while an elevated white cell count was predictive at 12 months for UC (P = 0.007).

Conclusion
Thiopurine withdrawal in the context of sustained remission is associated with a 1-year moderate-to-severe relapse rate of 23% in Crohn's disease and 12% in ulcerative colitis.

Aliment Pharmacol Ther
INTRODUCTION

Thiopurines have been in clinical use for 50 years and remain the backbone of maintenance strategies for IBD, either as monotherapy or in combination with an anti-tumour necrosis factor agent. Azathioprine (AZA) and its metabolite mercaptopurine (MP) are effective in maintaining clinical remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Around 10–28% of patients report side effects (most commonly nausea) of which 50–80% will discontinue the drug as a result. Thiopurines have a narrow therapeutic window and carry a risk of dose-dependent myelosuppression and serious adverse events. A subset of the population who carry two loss of function thiopurine methyltransferase (TPMT) alleles have the greatest risk of myelosuppression and serious adverse events. Continuous use of thiopurines has also been linked with malignancies such as lymphoma and non-melanoma skin cancer. A large prospective study of 19,486 IBD patients showed incidence rates of non-melanoma skin cancer for current and previous AZA use at 0.66/1000 and 0.38/1000 patient years respectively (age < 50) and a cumulative increase with age. Beaugerie showed an incidence rate of 0.9/1000 patient years for lymphoma in those receiving AZA (n = 19,486), casting doubt on its long-term safety. These long-term risks make clinicians and patients wary about indefinite use of thiopurines despite the risk of relapse on withdrawal.

The relapse rates after stopping thiopurines have been reported in CD at 21–41% at 1 year with a cumulative increase to 61–85% at 5 years. In UC, one randomised controlled trial and three retrospective studies showed relapse rates of 35–77% at 1 year and 65–75% at 5 years. However, most of these studies had patients on treatment for a short period of time (Table 1) and perhaps therefore overestimate the risk of disease relapse in patients who are in sustained clinical remission.

We aimed to examine relapse rates following thiopurine withdrawal along with predictive factors and the success of recapture in a large group of patients with at least 3 years of continuous thiopurine therapy for CD or UC.

METHODS

Study design

A retrospective multi-centre clinical audit was performed with patients identified from 11 IBD centres across the UK. Detailed case note review was performed in all patients using a standardised, pre-designed proforma. Data were collected for patient demographics including age, sex, weight, smoking status, age at diagnosis and date of diagnosis. Details of drug therapy included the type of thiopurine used, start date, initial dose and maximum dosage, age at withdrawal and any dose tapering at withdrawal, plus concomitant medications. Details of parameters at withdrawal included Montreal classification and behaviour, laboratory markers (C-reactive protein (CRP), haemoglobin, white cell count, platelets, albumin), endoscopic findings and reasons for withdrawal. Relapse was recorded including any change in drug therapy or reintroduction of thiopurines. Patients were identified by searching IBD databases and/or clinic lists of those attending out-patient IBD clinics to reduce the risk of bias from physicians recalling only those patients who had relapsed.

Inclusion criteria

Patients had a definitive diagnosis of UC or CD and continuous thiopurine use for at least 35 months. They were in clinical remission at the time of drug withdrawal as defined by physician global assessment and no use of corticosteroids within the preceding 6 months. The minimum follow-up time following withdrawal was 12 months (or moderate-to-severe relapse within 12 months). Patients were excluded if they were on concomitant anti-TNF therapy at the point of thiopurine withdrawal.

Disease relapse was defined by severity and categorised as mild, moderate or severe. Mild relapse was defined by the use of topical treatments or commencement of dose increase of oral 5-aminosalicylate (5-ASA) while moderate relapse was defined by the use of oral steroids or recommencement of thiopurine. Admission to hospital, surgery, use of intravenous corticosteroids or commencement of anti-TNF was considered a severe relapse.

At study design, primary end-point was defined as moderate-to-severe relapse at 12 months while secondary end-point was moderate-to-severe relapse at 24 months.

Statistical analysis

Data were analysed using Microsoft Excel 2010 (Microsoft, Redmond, WA, USA) and R 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). Continuous data are presented as medians and interquartile ranges and were analysed using a Mann–Whitney U-test. Categorical data are presented as numbers and percentages and were analysed using $\chi^2$ or Fisher’s exact tests as
appropriate. Survival analysis was done using Kaplan–Meier analysis in the survival package in R. Patients were censored at the point of most recent follow-up. Estimates of relapse rates for each severity category over time were generated from the overall survival function and the proportion of relapses of that category to that time point.

For analysis of predictive factors, each factor was analysed in those patients for whom those data were available. Patients with additional reasons for withdrawal that could potentially have influenced laboratory parameters were excluded from analysis of these parameters.

Multivariable analysis was performed using Cox Proportional Hazards. Backward stepwise regression was used to select variables for the final model. Variables that did not lead to a lower Akaike information criterion (AIC) were excluded in a stepwise manner, and finally variables whose hazard ratio had a 95% confidence interval that crossed one were excluded. Continuous data were then converted to categorical data by finding the thresholds that gave the lowest AIC for the fitted model.

RESULTS
Across all centres, 264 patients were submitted. 27 were excluded, for reasons detailed in Table S1, leaving 237 patients, 129 with CD and 108 with UC, in the primary analysis (Table 2; breakdown by study centre in Table S2). The median duration of thiopurine use prior to drug withdrawal was 6.0 years (IQR 4.4–8.2) for CD and 5.8 years (IQR 4.5–8.5) for UC. The median follow-up post drug withdrawal in those without relapse was 32 months (IQR 24–51) for CD and 36 months (IQR 21–52) for UC. Median CRP was 4.0 mg/L (IQR 2.5–6.0) in CD and 2.5 mg/L (IQR 2.5–4.0) in UC (Table 3).

All patients were in sustained clinical remission at the time of thiopurine withdrawal; 35/237 (22 CD; 13 UC) had an additional trigger for drug cessation (Table S3).
Thiopurines were tapered prior to withdrawal in 87 patients (37%). Data on length of taper were available in 48 of these patients, with a median duration of 12 weeks (IQR 8–26).

**Disease relapse and predictive factors: univariable analysis**

23% of CD patients had a moderate-to-severe relapse within 12 months of thiopurine withdrawal as compared to 12% in UC patients (Figure 1). There was a significant difference in survival without moderate-to-severe relapse between CD and UC assessed by logrank test ($P = 0.035$). CRP at time of drug withdrawal was associated with significantly greater relapse in CD within 12 months ($P = 0.005$) but was not predictive in UC (Table 4). Relapse at 12 months in CD was also associated with having tapered the thiopurine at withdrawal ($P = 0.004$). In the UC cohort, white cell counts at withdrawal were significantly higher in those who relapsed by 12 months ($P = 0.007$), although the upper quartile was still in the normal range.

**Multivariable analysis**

Disease location and the most significant univariable laboratory parameters (haemoglobin, white cell count and CRP) were included in multivariable models for CD and UC. The Cox proportional hazards method was used to create a model to assess the contribution of each variable to risk of relapse. After backwards stepwise exclusion of variables that did not contribute to the model, WCC and CRP remained for CD, and only WCC remained for UC (Table 5). Thresholds were then found to allow stratification of patients at higher and lower risk, and to allow creation of survival curves (Figure 2).

**Consequences of relapse**

Among all CD patients, by 12 months, 23 patients (18%) had required systemic corticosteroids, four patients (3%) had required anti-TNF therapy, seven patients (5%) had required hospital admission and five patients (4%) had required resectional surgery. Among all UC patients, by 12 months, six patients (6%) had required systemic steroids, one patient (1%) hospitalisation and no patient

### Table 2 | Study demographics, Montreal classification and disease behaviour for patients in clinical remission on thiopurines

| Variable | Crohn's disease, $n = 129$ | Ulcerative colitis, $n = 108$ |
|----------|-----------------------------|-----------------------------|
| Females (%) | 76 (59.8%) | 42 (39.6%) |
| Median (IQ range) age at withdrawal/years | 38 (28–48) | 42 (33–58) |
| Current smokers (%) | 23 (19.2%) | 4 (4.3%) |
| Median (IQR) duration thiopurine use/years | 6.0 (4.4–8.2) | 5.8 (4.4–8.5) |
| Range duration thiopurine use/years | 2.9–18.7 | 2.9–18.0 |
| Median (IQR) peak AZA dose/mg | 125 (100–150) | 150 (112–150) |
| Median (IQR) duration follow-up in those without relapse/months | 31.7 (23.9–50.8) | 36.0 (20.6–52.2) |
| Median year stopped AZA (range) | 2008 (1980–2012) | 2008 (1999–2011) |

Montreal location†

| L1 ± L4 | 29/123 (23.6%) |
| L2 ± L4 | 48/123 (39.0%) |
| L3 ± L4 | 44/123 (35.8%) |
| L4 | 2/123 (1.6%) |

Montreal behaviour†

| B1 | 88/123 (71.5%) |
| B2 | 16/123 (13.0%) |
| B3 | 19/123 (15.4%) |

Montreal extent‡

| E1 | 23/97 (23.7%) |
| E2 | 26/97 (26.8%) |
| E3 | 48/97 (49.5%) |

5ASA at time of withdrawal

| 40 (31.0%) | 83 (76.1%) |

* Smoking status unknown in 23 patients.
† Montreal location and behaviour unknown in six patients
‡ Montreal extent unknown in 11 patients.
required anti-TNF or resectional surgery. By the end of follow-up, a further three CD and two UC patients had required resectional surgery, although this was for dysplasia in one of the UC cases.

Within the 48 CD patients with a moderate-to-severe relapse at any point and did not require surgery or anti-TNF, 42 (88%) had a thiopurine re-introduced. Of those, reintroduction was successful in 31 (74%)
### Table 4 | Factors assessed against moderate-to-severe relapse by 12 months and diagnosis

|                  | Crohn’s disease | Ulcerative colitis |
|------------------|-----------------|--------------------|
|                  | No relapse by 12 months | Relapse by 12 months | P  | No relapse by 12 months | Relapse by 12 months | P  |
| Female sex       | 62/96 (64.6%)    | 14/29 (48.3%)      | 0.174 | 34/90 (37.8%) | 6/13 (46.2%) | 0.783 |
| Smoking status at withdrawal |                |                    |      |                |                    |      |
| Current          | 17/92 (18.5%)    | 6/27 (22.2%)       | 0.366 | 4/82 (4.9%)    | 0/10 (0.0%)    | 0.825 |
| Ex               | 15/92 (16.3%)    | 7/27 (25.9%)       | 24/82 (29.3%) | 4/10 (40.0%) |
| Never            | 60/92 (65.2%)    | 14/27 (51.9%)      | 54/82 (65.9%) | 6/10 (60.0%)  |
| Age at diagnosis | 24.0 (18.3–31.8) | 25.5 (19.2–35.1)  | 0.587 | 28.0 (19.3–41.0) | 28.0 (19.3–41.0) | 0.586 |
| Age when starting thiopurine | 29.0 (21.3–41.0) | 30.0 (22.5–43.0) | 0.988 | 36.0 (26.5–52.5) | 35.0 (27.0–44.0) | 0.723 |
| Additional reason for withdrawal | 19/98 (19.4%) | 2/29 (6.9%) | 0.156 | 10/92 (10.9%) | 2/13 (15.4%) | 0.642 |
| Maximum dose by weight (mg/kg) | 1.8 (1.5–2.2) | 1.9 (1.6–2.2) | 24/82 (29.3%) | 4/10 (40.0%) |
| Tapered at withdrawal | 27/98 (27.6%) | 17/29 (58.6%) | 0.004 | 34/92 (37.0%) | 7/13 (53.8%) | 0.387 |
| 5ASA at withdrawal | 26/98 (26.5%) | 12/29 (41.4%) | 0.193 | 71/92 (77.2%) | 9/13 (69.2%) | 0.504 |
| Montreal location |                  |                    |      |                |                    |      |
| L1 ± L4          | 25/94 (26.6%)    | 4/27 (14.8%)       | 0.096 |                |                    |      |
| L2 ± L4          | 30/94 (31.9%)    | 16/27 (59.3%)      | 37/94 (39.4%) | 7/27 (25.9%) |
| L3 ± L4          | 2/94 (2.1%)      | 0/27 (0.0%)        |      |                |                    |      |
| Montreal behaviour |                |                    |      |                |                    |      |
| B1               | 66/93 (71.0%)    | 20/28 (71.4%)      | 1.000 |                |                    |      |
| B2               | 12/93 (12.9%)    | 4/28 (14.3%)       |      |                |                    |      |
| B3               | 15/93 (16.1%)    | 4/28 (14.3%)       |      |                |                    |      |
| Montreal extent  |                  |                    |      |                |                    |      |
| E1               | 19/85 (22.4%)    | 4/10 (40.0%)       | 0.276 |                |                    |      |
| E2               | 22/85 (25.9%)    | 3/10 (30.0%)       | 44/85 (51.8%) | 3/10 (30.0%) |
| E3               | 149 (139–155) | 145 (140–151) | 0.496 |                |                    |      |
| Haemoglobin (g/L)* | 151 (145–159) | 143 (139–154) | 0.101 | 149 (139–155) | 145 (140–151) | 0.496 |
| White cell count (×10^9/L) | 6.2 (5.3–8.2) | 7.6 (5.5–8.6) | 0.270 | 5.9 (4.7–6.8) | 7.7 (6.5–9.4) | 0.007 |
| Platelets (×10^9/L) | 265 (220–316) | 268 (226–375) | 0.303 | 260 (213–312) | 290 (250.5–324) | 0.218 |
| CRP (mg/L)       | 4.0 (2.1–6.0)   | 7.0 (3.8–16.5)    | 0.005 | 2.5 (2.0–4.0) | 3.0 (2.8–4.5) | 0.286 |
| Albumin (g/L)    | 44.0 (41.0–46.0) | 43.0 (41.0–45.0)  | 0.259 | 45.0 (42.2–47.0) | 44.0 (41.0–45.0) | 0.187 |

* Haemoglobin for females scaled to male range to allow comparison across sexes.

P values less than 0.05 are highlighted in bold.

### Table 5 | Multivariable analysis of predictive factors for relapse following thiopurine withdrawal: final Cox proportional hazards model. (a) Crohn’s disease; (b) Ulcerative colitis

| Variable          | Hazard ratio (95% confidence interval) | P-value | Optimum threshold to split data | Hazard ratio when split by threshold (95% CI) | P-value when split by threshold |
|-------------------|----------------------------------------|---------|---------------------------------|-----------------------------------------------|---------------------------------|
|                   | Analysis as continuous variables       |         | Analysis as categorical variables |
| White cell count  | 1.18 (1.04–1.33)                       | 0.011   | ≥6.6 × 10^9/L                   | 3.75 (1.87–7.54)                               | 0.0002                         |
| C-reactive protein| 1.04 (1.00–1.07)                       | 0.035   | ≥14 g/L                        | 3.2 (1.48–7.05)                                | 0.003                          |
| White cell count  | 1.44 (1.11–1.87)                       | 0.007   | ≥9.1 × 10^9/L                   | 6.70 (1.86–24.2)                               | 0.004                          |
(a) Proportion without moderate to severe relapse 1.0

WCC < $6.6 \times 10^9$ L and CRP < 14 g/L ($n = 38$)

WCC $\geq 6.6 \times 10^9$ L or CRP $\geq 14$ g/L ($n = 35$)

WCC $\geq 6.6 \times 10^9$ L and CRP $\geq 14$ g/L ($n = 7$)

(b) Proportion without moderate to severe relapse 1.0

WCC < $9.1 \times 10^9$ L ($n = 87$)

WCC $\geq 9.1 \times 10^9$ L ($n = 7$)

Figure 2 | Survival analysis of relapse following withdrawal of thiopurines for sustained remission stratified by predictive factors in Crohn's disease (a) and ulcerative colitis (b).
although the majority (21/31, 68%) also required systemic steroids to reinduce remission. For UC patients, thiopurines were reintroduced in 24 of 34 (71%) patients with a moderate-to-severe relapse not requiring surgery or anti-TNF. This was successful in 22 patients (92%), with 11 (50%) requiring systemic steroids also.

DISCUSSION
In patients with CD, our study shows a moderate-to-severe relapse rate of 24% at 1 year and 39% at 2 years after thiopurine withdrawal. This is similar to published series showing a relapse rate of 21–41% with a cumulative increase in the rate with time (Table 1). In addition, our study demonstrates a significant greater relapse rate in CD patients compared to UC. While this study does not address the rate of flare in those continuing therapy, a recent meta-analysis showed that the odds ratio of a flare in those stopping azathioprine versus those continuing was 0.15 [95% Confidence Interval (CI) 0.05–0.44] at 12 months and 0.30 (95% CI 0.08–1.23) at 18 months.

Previous studies have shown that CRP of 20 mg/L or higher, a neutrophil count of $4.0 \times 10^9$/L, a haemoglobin (<12 g/dL), male gender, age ≥31 and duration of remission less than four years were factors predictive of relapse. However, duration of AZA/MP use and the definition of remission varied with each study making it difficult to compare their study outcomes. Fraser et al., with n = 222 patients (79 CD, 143 UC), found no correlation between disease flare and clinical or laboratory indices. Our study shows that CRP is highly predictive of relapse in this cohort, a finding similar to Lemann et al. Tapering of thiopurine prior to withdrawal was also noted here to be associated with relapse, but practice with relation to tapering was quite different between the included centres and it is likely the observed differences in relapse rates relate to other, unmeasured factors rather than tapering itself.

In patients with UC, our study showed a lower relapse rate of 11% at 12 months and 21% at 24 months. This contrasts with a relapse rate after drug withdrawal in other published studies as high as 35–77% at 1 year and 65–75% at 5 years (Table 1). We used strict criteria to define sustained remission which included continuous thiopurine use for a minimum ≥3 years and subsequent withdrawal when in sustained clinical remission (absence of symptoms and no corticosteroids for >6 months). This will have impacted the subsequent relapse rates.

In the UC cohort, our study shows that a raised white cell count is highly predictive of a relapse after drug withdrawal. Hawthorne et al. performed a small RCT trial and found younger age to be the statistically significant predictive factor for relapse. Cassinoti et al. performed a multicentre observational study of 127 UC patients and found that relapse during treatment with AZA, withdrawal of AZA due to drug toxicity and disease extent to be predictive of disease relapse at drug withdrawal. Patients in this study had concomitant aminosaliclylates, masking the true effects of AZA.

On the contrary, a large single centre study with 143 UC patients did not show any factors predictive of relapse.

The definition of clinical remission is important when evaluating drug withdrawal studies. Studies have used various clinical disease activity indices and laboratory markers to define clinical remission. Two randomised controlled trials used the Crohn’s Disease Activity Index (CDAI), while others used the Harvey Bradshaw Index (HBI). O’Donoghue et al. and Lobel et al. utilised the Physician Global Assessment (PGA) score to define remission and disease flare in CD. We used the PGA clinical index and corticosteroid use (in the last 6 months) to define remission.

Recapture data have only been reported by Treton et al. in CD patients where 22 of the 23 patients were successfully retreated with AZA. Although a small cohort, our study is the only study to show retreatment success in both disease groups. However, it should be noted that 25/29 patients with CD and moderate-to-severe relapse within 12 months (20% of the overall CD cohort) required systemic steroids, anti-TNF or hospital admission and five of these patients required resectional surgery. Further large studies are needed to ascertain re-treatment success as this would have an impact on our decisions to withdraw thiopurines.

With high cumulative relapse rates after thiopurine withdrawal in sustained remission, devising a set of key relapse indicators that encompass clinical, endoscopic and laboratory markers would be beneficial. Our study highlights the importance of risk stratification in patients before considering drug withdrawal. The knowledge of these predictive factors may be translated onto the anti-TNF group of patients; however, multicentre trials are required to validate this. The STORI study, looking at infliximab withdrawal in CD remission showed that the presence of no more than two risk factors (a combination of clinical and biological markers) carried a 15% risk of relapse at 1 year. Similarly, risk stratification in patients on long-term AZA/MP treatment who are risk of disease flare post drug withdrawal.
withdrawal can be adopted in clinical practice. Future studies could use pre-defined risk groups to assess relapse rates post drug withdrawal.

In addition to risk factors for disease relapse, adverse events with long-term use must be taken into account when considering drug withdrawal. The small but definite association of non-melanoma skin cancer and lymphoma with long-term thiopurine use has been reported. The risk of non-melanoma cancer is greater when treating older patients with IBD. In addition, the comorbidity rate is significantly higher in the elderly group (age >65 years) with IBD. With an ageing population worldwide, the number of older patients with IBD is also expected to increase. Therefore, treatment strategies with thiopurines would need further evaluation and a careful consideration.

The key strengths of our study are threefold. Our study is one of the largest to date looking at AZA/MP withdrawal. While many studies used varied parameters to define remission, we used strict clinical parameters with at least 3 years of continuous thiopurine use prior to drug withdrawal.

Patients within this study were selected for withdrawal by their physicians on the basis of their assessment, and so the withdrawal rates may not be generalisable to all patients in clinical remission. For example, physicians may have been less likely to withdraw patients with perianal disease or rectal disease. There were also limited data available on faecal calprotectin; it is likely that an accurate marker of endoscopic disease activity would prove highly useful in predicting relapse in this context, as has been seen for infliximab withdrawal in the STORI study. The study may have been underpowered to fully assess the predictive power of all of the factors assessed.

Thiopurines remain an integral part of disease management in IBD patients with evidence of its role in sustaining long-term remission. However, bearing in mind the side effects and risks of malignancy with long-term immunosuppression, it is crucial to identify a sub-cohort who are at highest risk of disease flare. Our study and data from the STORI trial suggest that patients in clinical and biochemical remission have a low risk of relapse. Of those who relapse after drug withdrawal, reintroduction of thiopurines allows recapture in the majority of IBD patients, particularly in UC. However, in a select group of patients (CD cohort), long-term thiopurines may be in their best interest, especially if the consequences of disease flare have an impact on morbidity and subsequent remission rates.

**AUTHORSHIP**

*Guarantor of the article:* Dr Charlie Lees.

*Author contributions:* NAK and CWL conceived the study. PI, JM, MP, TA, JRFC, IA, JS, AJL, MS, JOL, CWL co-ordinated data collection at their respective sites. BW, CJG, RM, SR, RD, NH, RF, SM, SMS, CAL, HAH, DG collected the data. NAK aggregated the data and performed analysis. RK wrote the initial draft of the manuscript. NAK and CWL co-ordinated revision of the manuscript as guided by all of the authors who approved the final version of the manuscript.

**ACKNOWLEDGEMENTS**

*Declaration of personal interests:* NAK has served as a speaker for Warner Chilcott, Abbvie and MSD, and has had support to attend meetings from Shire. He has research funding from the Wellcome Trust [097943].

CAL has served as a speaker for Genentech, and has received research funding from the Wellcome Trust [093885], Genentech, Techlab, Immundiagnostik and Roche tissue diagnostics.

PMI has served as a speaker, a consultant and/or an advisory board member for AbbVie, Ferring, Ferrinject, Genentech, Johnson and Johnson, MSD, Pharmacosmos, Shire, Symprove, Takeda, Tillotts and Warner-Chilcott, and has received research funding from Genentech and Theradiag.

JM has served as a consultant and an advisory board member for Genentech and Tillotts Pharmaceuticals, and has received research funding from Genentech.

TA has served as an speaker, a consultant and an advisory board member for AbbVie, MSD, Ferring, Warner Chilcott, and Napp pharmaceuticals. He has received research funding from Crohn’s and colitis UK, CORE, the International serious adverse events consortium, AbbVie and MSD.

IDRA has been an advisory board member for Vifor and has had travel supported by Shire. J. Satsangi has served as a speaker, a consultant and an advisory board member for MSD, Ferring, Abbvie and Shire, and has received research funding from Abbvie.

JS has served as a speaker, a consultant and an advisory board member for MSD, Ferring Abbvie and Shire, and has received research funding from Abbvie.

MS has acted as a speaker for Warner Chilcott and the Falk Foundation, and as a consultant for Abbvie.

JOL has served as a speaker, consultant or advisory board member for Abbvie, Atlantic Healthcare, Ferring, MSD, Takeda, Shire and Warner Chilcott and received research funding from MSD, Shire and Takeda.
CWL has served as an speaker, a consultant and an advisory board member for Abbvie, MSD, Hospira, Pharmacosmos, Vifor Pharma, Dr Falk, Takeda, Warner Chilcott, and Shire, and has received research funding from Abbvie and Shire.

RK, BW, CJG, RM, SR, RD, RN, RF, RH, SM, SMS, HAH, AJL, MP, JRFC have no personal interests to declare.

Declaration of funding interests: Dr Nick Kennedy is supported by a grant from the Wellcome Trust [097943]. Dr Christopher Lamb is supported by a grant from the Wellcome Trust [093885/Z/10/Z].

SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Table S1. Reasons for exclusion from primary cohort.
Table S2. Numbers of included patients from each centre.
Table S3. Reasons for thiopurine withdrawal in addition to sustained remission in Crohn’s disease and ulcerative colitis.

REFERENCES
1. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn’s disease. Lancet 1969; 2: 612–4.
2. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 674–8.
3. O’Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 1978; 2: 955–7.
4. Present DH, Korolitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7.
5. Markowitz J, Grencher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119: 895–902.
6. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132–42.
7. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000; 2: CD000067.
8. Timmer A, McDonald JWD, Tsoullis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9: CD006478.
9. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485–9.
10. Chaparro M, Ordás I, Cabrè E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013; 19: 1404–10.
11. Connell WR, Kam M, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081–5.
12. Anstey A, Lennard M, Mayou SC, et al. Pancyclopaenia related to azathioprine—an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992; 85: 752–6.
13. Gisbert JP, Gonzalez-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102: 1518–27.
14. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025–30.
15. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621–8; e1–5.
16. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617–25.
17. Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215–9.
18. Treton X, Bouhnik Y, Mary J-Y, et al. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80–5.
19. Lémann M, Mary J-Y, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812–8.
20. Kim PS, Zlatanic J, Korolitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol 1999; 94: 3254–7.
21. Vilien M, Dahlerup JF, Munck LK, et al. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: increased relapse rate the following year. Aliment Pharmacol Ther 2004; 19: 1147–52.
22. Lobel EZ, Korolitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004; 99: 462–5.
23. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760–7.
24. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20–2.
25. French H, Mark Dalzell A, Srinivasan R, et al. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn’s disease: a meta-analysis. Dig Dis Sci 2011; 56: 1922–36.
26. Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimitabolite therapy after infliximab
therapy is stopped. *Gastroenterology* 2012; **142**:63–70 e5; quiz e31.

27. Cottone M, Kohn A, Daperno M, *et al.* Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2011; **9**:30–5.

28. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. *Dig Dis Sci* 2013; **58**:1306–12.

29. Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. *Curr Gastroenterol Rep* 2013; **15**:310.

30. D’Haens G, Ferrante M, Vermeire S, *et al.* Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. *Inflamm Bowel Dis* 2012; **18**:2218–24.

31. Sokol H, Seksik P, Nion-Larmurier I, *et al.* Current smoking, not duration of remission, delays Crohn’s disease relapse following azathioprine withdrawal. *Inflamm Bowel Dis* 2010; **16**:362–3.